Octavio Espinoza sold $9.2M of LGND
Chief Financial Officer at LIGAND PHARMACEUTICALS INC. 31,641 shares at an average of $292.07, traded Aug 12, 2026, filed Aug 14, 2026.
Score components
- +22RoleCFO
- +25Trade size$9.2M at market
- +20Share of holdings soldSold 53% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002001011-26-000115, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | MOption exercise Common Stock10b5-1 | +16,179 | $52.84 | $855k | 43,875 | Aug 14, 2026 |
| Aug 12, 2026 | MOption exercise Common Stock10b5-1 | +2,074 | $70.04 | $145k | 45,949 | Aug 14, 2026 |
| Aug 12, 2026 | MOption exercise Common Stock10b5-1 | +2,869 | $55.75 | $160k | 48,818 | Aug 14, 2026 |
| Aug 12, 2026 | MOption exercise Common Stock10b5-1 | +7,171 | $57.22 | $410k | 55,989 | Aug 14, 2026 |
| Aug 12, 2026 | MOption exercise Common Stock10b5-1 | +3,348 | $68.74 | $230k | 59,337 | Aug 14, 2026 |
| Aug 12, 2026 | SOpen-market sale Common Stock10b5-1 | -31,641 | $292.07 | $9.2M | 27,696 | Aug 14, 2026 |
| Aug 12, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,869 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Aug 12, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -7,171 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Aug 12, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -16,179 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Aug 12, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -3,348 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Aug 12, 2026 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -2,074 | $0.00 | $0 | 0 | Aug 14, 2026 |
Related signals
Other insiders at LIGAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.5M 5,000 shares | -14% | |
| 43Moderate | LIGAND PHARMACEUTICALS INC | Martine Zimmermann director | $342k 1,200 shares | -24% | |
| 33Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -12% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | Jason Haas director | $2.1M 7,138 shares | -64% | |
| 25Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -11% | |
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.6M 5,000 shares | -11% | |
| 34Weak | LIGAND PHARMACEUTICALS INC | Stephen L Sabba director | $545k 2,145 shares | -6% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | Jason Haas director | $1.7M 6,461 shares | -56% | |
| 55Moderate | LIGAND PHARMACEUTICALS INC | Jason Aryeh director | $1.3M 5,000 shares | -5% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | John L Lamattina director | $1.2M 4,591 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.